Cargando…

Discovery of novel SARS-CoV-2 inhibitors targeting the main protease M(pro) by virtual screenings and hit optimization

Two years after its emergence, SARS-CoV-2 still represents a serious and global threat to human health. Antiviral drug development usually takes a long time and, to increase the chances of success, chemical variability of hit compounds represents a valuable source for the discovery of new antivirals...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mercorelli, Beatrice, Desantis, Jenny, Celegato, Marta, Bazzacco, Alessandro, Siragusa, Lydia, Benedetti, Paolo, Eleuteri, Michela, Croci, Federico, Cruciani, Gabriele, Goracci, Laura, Loregian, Arianna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier B.V. 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9172283/ https://www.ncbi.nlm.nih.gov/pubmed/35688349 http://dx.doi.org/10.1016/j.antiviral.2022.105350

Ejemplares similares

Indomethacin-based PROTACs as pan-coronavirus antiviral agents
por: Desantis, Jenny, et al.
Publicado: (2021)

Understanding the Metabolism of Proteolysis Targeting Chimeras (PROTACs): The Next Step toward Pharmaceutical Applications
por: Goracci, Laura, et al.
Publicado: (2020)

Targeted Disruption of E6/p53 Binding Exerts Broad Activity and Synergism with Paclitaxel and Topotecan against HPV-Transformed Cancer Cells
por: Celegato, Marta, et al.
Publicado: (2021)

A quantitative LumiFluo assay to test inhibitory compounds blocking p53 degradation induced by human papillomavirus oncoprotein E6 in living cells
por: Messa, Lorenzo, et al.
Publicado: (2018)

PROTACs bearing piperazine-containing linkers: what effect on their protonation state?
por: Desantis, Jenny, et al.
Publicado: (2022)

The Dimeric Form of HPV16 E6 Is Crucial to Drive YAP/TAZ Upregulation through the Targeting of hScrib
por: Messa, Lorenzo, et al.
Publicado: (2021)

Drug Repurposing for Viral Infectious Diseases: How Far Are We?
por: Mercorelli, Beatrice, et al.
Publicado: (2018)

Early inhibitors of human cytomegalovirus: State-of-art and therapeutic perspectives
por: Mercorelli, Beatrice, et al.
Publicado: (2011)

Drug Repurposing Campaigns for Human Cytomegalovirus Identify a Natural Compound Targeting the Immediate-Early 2 (IE2) Protein: A Comment on “The Natural Flavonoid Compound Deguelin Inhibits HCMV Lytic Replication within Fibroblasts”
por: Mercorelli, Beatrice, et al.
Publicado: (2019)

Binding parameters and thermodynamics of the interaction of the human cytomegalovirus DNA polymerase accessory protein, UL44, with DNA: implications for the processivity mechanism
por: Loregian, Arianna, et al.
Publicado: (2007)

Divide et impera: An In Silico Screening Targeting HCMV ppUL44 Processivity Factor Homodimerization Identifies Small Molecules Inhibiting Viral Replication
por: Ghassabian, Hanieh, et al.
Publicado: (2021)

Small-Molecule Inhibitor of Flaviviral NS3-NS5 Interaction with Broad-Spectrum Activity and Efficacy In Vivo
por: Celegato, Marta, et al.
Publicado: (2023)

Hit Expansion of a Noncovalent SARS-CoV-2 Main Protease Inhibitor
por: Glaser, Jens, et al.
Publicado: (2022)

Structure-Based Virtual Screening and Functional Validation of Potential Hit Molecules Targeting the SARS-CoV-2 Main Protease
por: Moovarkumudalvan, Balasubramanian, et al.
Publicado: (2022)

MassChemSite for In-Depth Forced Degradation Analysis of PARP Inhibitors Olaparib, Rucaparib, and Niraparib
por: Bonciarelli, Stefano, et al.
Publicado: (2023)

The Human Cytomegalovirus DNA Polymerase Processivity Factor UL44 Is Modified by SUMO in a DNA-Dependent Manner
por: Sinigalia, Elisa, et al.
Publicado: (2012)

Diphenyl Diselenide and SARS-CoV-2: in silico Exploration of the Mechanisms of Inhibition of Main Protease (M(pro)) and Papain-like Protease (PL(pro))
por: Omage, Folorunsho Bright, et al.
Publicado: (2023)

A Review of the Current Landscape of SARS-CoV-2 Main Protease Inhibitors: Have We Hit the Bullseye Yet?
por: Macip, Guillem, et al.
Publicado: (2021)

QM/QM studies for Michael reaction in coronavirus main protease (3CL(Pro))
por: Taranto, Alex G., et al.
Publicado: (2008)

A Point Mutation in a Herpesvirus Polymerase Determines Neuropathogenicity
por: Goodman, Laura B, et al.
Publicado: (2007)

Inhibition of the SARS-CoV-2 3CL(pro) main protease by plant polyphenols
por: Bahun, Miha, et al.
Publicado: (2022)

Expression, purification, and biophysical characterization of recombinant MERS-CoV main (M(pro)) protease
por: Almutairi, Ghada Obeid, et al.
Publicado: (2022)

The temperature-dependent conformational ensemble of SARS-CoV-2 main protease (M(pro))
por: Ebrahim, Ali, et al.
Publicado: (2021)

Review on development of potential inhibitors of SARS-CoV-2 main protease (M(Pro))
por: Katre, Soumya Gulab, et al.
Publicado: (2022)

In silico analysis of echinocandins binding to the main proteases of coronaviruses PEDV (3CL(pro)) and SARS-CoV-2 (M(pro))
por: Vergoten, Gérard, et al.
Publicado: (2021)

Development of Broad‐Spectrum Halomethyl Ketone Inhibitors Against Coronavirus Main Protease 3CL(pro)
por: Bacha, Usman, et al.
Publicado: (2008)

In silico analysis of selected alkaloids against main protease (M(pro)) of SARS-CoV-2
por: Garg, Saksham, et al.
Publicado: (2020)

Microbial Natural Products as Potential Inhibitors of SARS-CoV-2 Main Protease (M(pro))
por: Sayed, Ahmed M., et al.
Publicado: (2020)

In silico approach for identification of natural compounds as potential COVID 19 main protease (M(pro)) inhibitors
por: Chaturvedi, Monika, et al.
Publicado: (2021)

Virtual and In Vitro Screening of Natural Products Identifies Indole and Benzene Derivatives as Inhibitors of SARS-CoV-2 Main Protease (M(pro))
por: Ang, Dony, et al.
Publicado: (2023)

Computer-aided drug design for virtual-screening and active-predicting of main protease (M(pro)) inhibitors against SARS-CoV-2
por: Dai, Renhui, et al.
Publicado: (2023)

In silico investigation of saponins and tannins as potential inhibitors of SARS-CoV-2 main protease (M(pro))
por: Falade, Victoria Adeola, et al.
Publicado: (2021)

Drug repurposing and computational modeling for discovery of inhibitors of the main protease (M(pro)) of SARS-CoV-2
por: Silva, José Rogério A., et al.
Publicado: (2021)

The temperature-dependent conformational ensemble of SARS-CoV-2 main protease (M(pro))
por: Ebrahim, Ali, et al.
Publicado: (2022)

The SARS‐CoV‐2 main protease (M(pro)): Structure, function, and emerging therapies for COVID‐19
por: Hu, Qing, et al.
Publicado: (2022)

Autochthonous Peruvian Natural Plants as Potential SARS-CoV-2 M(pro) Main Protease Inhibitors
por: Peralta-Moreno, Maria Nuria, et al.
Publicado: (2023)

Protegrin-2, a potential inhibitor for targeting SARS-CoV-2 main protease M(pro)
por: Jan, Zainab, et al.
Publicado: (2023)

One-Hit Wonders and 2-Hit Tubers: A Second-Hit to TSC2 Causes Tuber-Like Cells in Spheroids
por: Goswami, Sonal, et al.
Publicado: (2019)

Designing of improved drugs for COVID-19: Crystal structure of SARS-CoV-2 main protease M(pro)
por: Mengist, Hylemariam Mihiretie, et al.
Publicado: (2020)

Are vanadium complexes druggable against the main protease M(pro) of SARS-CoV-2? – A computational approach
por: Scior, Thomas, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_k1cdrdihmctplkflphdf5oss2j